King Luther Capital Management Corp Grows Stake in Boston Scientific Corporation $BSX

King Luther Capital Management Corp grew its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 350.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 46,851 shares of the medical equipment provider’s stock after purchasing an additional 36,454 shares during the period. King Luther Capital Management Corp’s holdings in Boston Scientific were worth $4,574,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BSX. Brighton Jones LLC grew its stake in shares of Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares during the last quarter. Stephens Inc. AR boosted its stake in Boston Scientific by 10.7% in the 2nd quarter. Stephens Inc. AR now owns 10,846 shares of the medical equipment provider’s stock worth $1,165,000 after purchasing an additional 1,046 shares in the last quarter. D.A. Davidson & CO. boosted its stake in Boston Scientific by 9.5% in the 2nd quarter. D.A. Davidson & CO. now owns 12,632 shares of the medical equipment provider’s stock worth $1,357,000 after purchasing an additional 1,096 shares in the last quarter. Rehmann Capital Advisory Group grew its position in Boston Scientific by 5.6% during the 2nd quarter. Rehmann Capital Advisory Group now owns 5,878 shares of the medical equipment provider’s stock worth $631,000 after purchasing an additional 311 shares during the last quarter. Finally, Freedom Investment Management Inc. increased its stake in Boston Scientific by 51.2% during the 2nd quarter. Freedom Investment Management Inc. now owns 8,129 shares of the medical equipment provider’s stock valued at $873,000 after purchasing an additional 2,751 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms have recently commented on BSX. The Goldman Sachs Group set a $99.00 price objective on shares of Boston Scientific in a report on Thursday, February 5th. UBS Group dropped their price target on Boston Scientific from $140.00 to $120.00 and set a “buy” rating on the stock in a research note on Thursday, February 5th. Royal Bank Of Canada cut their price objective on Boston Scientific from $130.00 to $115.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. TD Cowen decreased their target price on Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a report on Monday, February 2nd. Finally, Stifel Nicolaus dropped their target price on Boston Scientific from $125.00 to $110.00 and set a “buy” rating on the stock in a research report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $108.36.

Boston Scientific Stock Down 1.6%

Shares of BSX opened at $74.54 on Friday. The company has a market capitalization of $110.61 billion, a price-to-earnings ratio of 38.42, a PEG ratio of 1.05 and a beta of 0.67. Boston Scientific Corporation has a 52 week low of $72.69 and a 52 week high of $109.50. The stock’s 50-day moving average price is $89.23 and its 200-day moving average price is $96.63. The company has a quick ratio of 0.96, a current ratio of 1.62 and a debt-to-equity ratio of 0.46.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. The company had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.Boston Scientific’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, sell-side analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.